×




Gilead: Hepatitis-C Access Strategy (A) Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Gilead: Hepatitis-C Access Strategy (A) case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Gilead: Hepatitis-C Access Strategy (A) case study is a Harvard Business School (HBR) case study written by V. Kasturi Rangan, Vikram Rangan, David E. Bloom. The Gilead: Hepatitis-C Access Strategy (A) (referred as “Hepatitis Gilead” from here on) case study provides evaluation & decision scenario in field of Sales & Marketing. It also touches upon business topics such as - Value proposition, Health, Pricing.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Gilead: Hepatitis-C Access Strategy (A) Case Study


Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of this was accomplished through generic licensing, which brought a $10,000/year treatment regimen down to $100! Should the company replicate that strategy for Hepatitis C? If so, how would its US Healthcare customers, who were paying $84,000 per patient, react? On the other hand, Gilead had to balance the interests of its shareholders, who paid $11 billion for an acquisition that led to the new Hepatitis C drug.


Case Authors : V. Kasturi Rangan, Vikram Rangan, David E. Bloom

Topic : Sales & Marketing

Related Areas : Health, Pricing




Calculating Net Present Value (NPV) at 6% for Gilead: Hepatitis-C Access Strategy (A) Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10020623) -10020623 - -
Year 1 3471898 -6548725 3471898 0.9434 3275375
Year 2 3978138 -2570587 7450036 0.89 3540529
Year 3 3973066 1402479 11423102 0.8396 3335863
Year 4 3228869 4631348 14651971 0.7921 2557567
TOTAL 14651971 12709334




The Net Present Value at 6% discount rate is 2688711

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Internal Rate of Return
2. Net Present Value
3. Payback Period
4. Profitability Index

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Hepatitis Gilead shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Hepatitis Gilead have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.






Formula and Steps to Calculate Net Present Value (NPV) of Gilead: Hepatitis-C Access Strategy (A)

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Sales & Marketing Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Hepatitis Gilead often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Hepatitis Gilead needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10020623) -10020623 - -
Year 1 3471898 -6548725 3471898 0.8696 3019042
Year 2 3978138 -2570587 7450036 0.7561 3008044
Year 3 3973066 1402479 11423102 0.6575 2612355
Year 4 3228869 4631348 14651971 0.5718 1846116
TOTAL 10485557


The Net NPV after 4 years is 464934

(10485557 - 10020623 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10020623) -10020623 - -
Year 1 3471898 -6548725 3471898 0.8333 2893248
Year 2 3978138 -2570587 7450036 0.6944 2762596
Year 3 3973066 1402479 11423102 0.5787 2299228
Year 4 3228869 4631348 14651971 0.4823 1557132
TOTAL 9512204


The Net NPV after 4 years is -508419

At 20% discount rate the NPV is negative (9512204 - 10020623 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Hepatitis Gilead to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Hepatitis Gilead has a NPV value higher than Zero then finance managers at Hepatitis Gilead can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Hepatitis Gilead, then the stock price of the Hepatitis Gilead should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Hepatitis Gilead should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What will be a multi year spillover effect of various taxation regulations.

What can impact the cash flow of the project.

Understanding of risks involved in the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Gilead: Hepatitis-C Access Strategy (A)

References & Further Readings

V. Kasturi Rangan, Vikram Rangan, David E. Bloom (2018), "Gilead: Hepatitis-C Access Strategy (A) Harvard Business Review Case Study. Published by HBR Publications.


ChemoCentryx SWOT Analysis / TOWS Matrix

Healthcare , Biotechnology & Drugs


Zhejiang Meili High Tech SWOT Analysis / TOWS Matrix

Basic Materials , Misc. Fabricated Products


New Delhi Television SWOT Analysis / TOWS Matrix

Services , Broadcasting & Cable TV


Tianda Pharmas SWOT Analysis / TOWS Matrix

Healthcare , Biotechnology & Drugs


Oakajee Corporation Ltd SWOT Analysis / TOWS Matrix

Capital Goods , Construction - Raw Materials


Intertape Polymer SWOT Analysis / TOWS Matrix

Basic Materials , Containers & Packaging


Powerhouse Ventures SWOT Analysis / TOWS Matrix

Financial , Misc. Financial Services


PCCW SWOT Analysis / TOWS Matrix

Services , Communications Services


Yes24 SWOT Analysis / TOWS Matrix

Services , Retail (Catalog & Mail Order)


PB Bancorp SWOT Analysis / TOWS Matrix

Financial , Regional Banks